- Active not recruitingPHASE1
Phase I Trial of Defactinib and VS-6766.
This study is testing two new drugs, Defactinib and VS-6766, for patients with advanced cancers like certain lung, ovarian, womb, and pancreatic cancers. It aims to find the safest dose and see how well the combination works.
For: NSCLC · Low Grade Serous Ovarian Cancer · Endometrioid CarcinomaUnited Kingdom - RecruitingPHASE1, PHASE2
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
This study is testing two new drugs, avutometinib and defactinib, alone and with temozolomide, for people with aggressive brain tumours like glioblastoma. It aims to see if they are safe and can shrink tumours, particularly in patients with specific genetic changes.
For: Glioblastoma Multiforme (GBM) · Glioblastoma Multiform (Grade IV Astrocytoma) · Diffuse Hemispheric Glioma, H3 G34-MutantUnited Kingdom - RecruitingPHASE3
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
This study looks at a new drug combination, avutometinib and defactinib, for low-grade serous ovarian cancer that has come back. It compares this new treatment to standard options to see which works best and is safest for patients.
For: Low Grade Serous Ovarian CancerUnited States · Australia · Belgium